CDT Equity Welcomes U.S. Regulatory Development Supporting Expanded Access to Compounded Peptides
CDT Equity welcomed a new HHS interim enforcement discretion policy covering six peptide bulk drug substances, including BPC-157 and TB-500, while FDA rulemaking on the Section 503A Bulks List continues. Under the policy, HHS does not intend to take enforcement action against qualifying pharmacies, federal facilities, or licensed physicians compounding the specified peptides, subject to Section 503A conditions. CDT believes the development supports its strategic investment in U.S.
Key figures
- Covered peptides
- ["BPC-157","Epitalon","KPV","MOTS-c","Semax","TB-500"]
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.